Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …

CAR-T therapies to treat T-cell malignancies face unique hurdles. Normal and malignant T
cells usually express the same target for CAR, leading to fratricide. CAR-T cells targeting …

Mucin-domain glycoproteins are densely O-glycosylated and play critical roles in a host of
biological functions. In particular, the T cell immunoglobulin and mucin-domain containing …

CAR T cells recognizing CD19 effectively treat relapsed and refractory B-ALL and DLBCL.
However, CD19 loss is a frequent cause of relapse. Simultaneously targeting a second …

Chimeric Antigen Receptor (CAR) T-cell therapy is a promising treatment option for patients
suffering from B-cell-and plasma cell-derived hematologic malignancies and is being …

Proximity labeling proteomics (PLP) strategies are powerful approaches to yield snapshots
of protein neighborhoods. Here, we describe a multiscale PLP method with adjustable …

Chimeric antigen receptors (CARs) can redirect T cells to target abnormal cells, but their
activity is limited by a profound defect in antigen sensitivity, the source of which remains …

Two types of engineered T cells have been successfully used to treat patients with cancer,
one with an antigen recognition domain derived from antibodies [chimeric antigen receptors …

Background The paucity of tumor-specific targets for chimeric antigen receptor (CAR) T-cell
therapy of solid tumors necessitates careful preclinical evaluation of the therapeutic window …

Mesothelin (MSLN) has been a validated tumor-associated antigen target for several solid
tumors for over a decade, making it an attractive option for therapeutic interventions. Novel …